Since our inception in 1995, Simcere has grown from a pharmaceutical distributor to a prolific and innovative engine, with our understanding of innovation constantly expanding in scope and complexity. This journey has deepened our appreciation for innovation in creating value and enhancing corporate competitiveness. In April 2007, Simcere became the first Chinese chemical and biologica pharmaceutical company to list on the NYSE, with IPO proceeds of $261 million. Since then, we have invested six to eight percent of our annual revenue in research and development.

We believe the primary responsibilities of a pharmaceutical company are to provide greater access to medicine and more effective treatment options for doctors and patients. Quality therapies are always in short supply and Simcere¡¯s mission is to develop more effective therapies through continuous innovation.

With a clear path set by our corporate mission, we are committed to high-quality initiatives, which deliver long-term success and growth. With our devotion to the well-being of patients, we breathe creativity and ingenuity when tackling challenges and our employees¡¯ dedication is a strong driving force for innovation.

In 2010, we filed Investigational New Drug (IND) applications for five new candidate products, under the SFDA¡¯s Category I New Drug requirement. This was a major milestone in Simcere¡¯s history and a first in China¡¯s domestic pharmaceutical industry. This was a major step in Simcere¡¯s quest to develop and offer more effective medicines for patients. We will continue our pursuit of investing resources and applying our strengths in innovation, to achieve our vision of building a better future for patients.

Jinsheng Ren
Founder, Chairman, and Chief Executive Officer